Methods Projects

We will update our previous study to describe fluoroquinolone utilization trends from 2008 to 2022 and to assess the impact of the risk minimization measures introduced by Health Canada in 2017.

This study will replicate a FDA Sentinel study using the CNODES' adaptation of the Sentinel Common Data Model with Canadian data to determine whether there is an increased risk of intentional self-harm among adult patients with diabetes who are newly treated with GLP-1 receptor agonists compared to those who are newly treated with SGLT-2 inhibitors or DPP-4 inhibitors.

This pilot project aims to conduct a cohort study in 4 Canadian provinces to demonstrate the feasibility of replicating a US FDA Sentinel TreeScan signal-detection analysis using Ozempic as the case study.

This study will determine the percentage of patients with familial hypercholesterolemia achieving the public drug plans' recommended treatment goals with PCSK9 inhibitors and estimate the incidence of major adverse cardiovascular events among patients with familial hypercholesterolemia whore prescribed PCSK9 inhibitors. This project is a collaboration with ADTEC.

This study will describe the utilization of long-acting inhaled therapies for COPD in 6 provinces between 2012 and 2024, describing the characteristics of patients at treatment initiation and how treatment evolves over time.

The current available real-world evidence on the potential association between GLP-1 receptor agonists and the risk of suicidality and self-harm is limited, as the studies had contradictory findings and important methodological limitations.